Vista Pharmaceuticals

11.22
+0.38
(3.51%)
Market Cap
66.70 Cr
EPS
-1.03
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
16.59
52 Week Low
9.10
PB Ratio
1.05
Debt to Equity
0.23
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,667.20
#1 4,02,056.60
34.87
#1 49,887.20
12.06
#1 9,648
-18.99
44.96
6,856.50
1,80,770.80
83.01
8,184.00
0.89
1,600
23.05
66.42
1,515.70
1,21,632.70
23.79
28,409.50
7.12
5,291
30.28
55.73
3,416.70
1,15,349.00
59.96
10,785.70
11.59
1,656
10.91
71.04
1,276.80
1,07,100.50
#1 18.85
28,905.40
12.36
5,578
21.14
44.33
1,002.50
99,612.10
21.58
19,831.50
13.82
3,831
-0.19
73.16
2,287.00
95,744.80
47.55
10,615.60
19.57
1,942
-10.91
35.59
1,960.90
88,507.60
27.30
20,141.50
#1 19.94
1,936
#1 112.49
48.59
34,665.00
75,796.30
52.13
6,097.20
10.80
1,201
27.83
68.86
1,132.50
65,909.40
19.04
29,559.20
17.55
3,169
-0.50
48.07
Forecast
Actual
Growth Rate
Revenue Growth
657.14 %
Net Income Growth
-21.05 %
Cash Flow Change
-187.13 %
ROE
-27.69 %
ROCE
-18.17 %
EBITDA Margin (Avg.)
-90.26 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
Revenue
14
15
24
29
34
27
2
1
1
11
11
Expenses
11
13
21
24
30
28
3
2
5
14
14
EBITDA
3
3
3
6
4
-1
-2
-1
-4
-3
-4
Operating Profit %
20 %
17 %
13 %
18 %
4 %
-21 %
-137 %
-321 %
-443 %
-32 %
-41 %
Depreciation
1
1
1
1
1
1
1
1
1
1
1
Interest
0
1
1
2
2
2
2
1
1
1
1
Profit Before Tax
1
1
1
3
1
-4
-4
-3
-6
-5
-5
Tax
-0
0
0
1
0
-0
-2
-2
-0
-1
0
Net Profit
1
1
1
2
1
-4
-2
-1
-6
-5
-5
EPS in ₹
0.54
0.31
0.46
0.76
0.31
-1.22
-0.54
-0.24
-1.54
-1.03
-1.20

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
23
26
42
53
53
51
51
56
56
58
60
Fixed Assets
11
10
14
18
21
21
20
19
20
19
29
Current Assets
12
16
26
28
23
21
15
24
24
23
15
Capital Work in Progress
0
0
2
7
9
9
9
9
9
10
10
Investments
0
0
0
0
0
0
0
0
0
0
8
Other Assets
12
16
26
28
24
22
22
27
27
29
0
Total Liabilities
23
26
42
53
53
51
51
56
56
58
60
Current Liabilities
12
7
19
15
11
16
9
13
14
15
12
Non Current Liabilities
0
8
6
6
6
6
9
8
5
3
3
Total Equity
10
11
17
32
36
30
33
36
37
41
45
Reserve & Surplus
5
6
11
26
30
24
26
28
23
26
33
Share Capital
5
5
5
6
6
6
7
7
8
9
12

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
0
0
5
-4
-1
-1
-0
-0
0
-0
Investing Activities
-0
-0
-4
-11
-6
-2
-0
0
-1
-1
Operating Activities
-4
-3
3
-5
3
1
-7
-1
-2
-5
Financing Activities
4
3
6
11
1
0
7
1
3
6

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
35.29 %
35.29 %
36.94 %
36.94 %
35.44 %
35.44 %
35.44 %
35.44 %
35.44 %
30.49 %
29.51 %
27.81 %
27.81 %
21.19 %
21.19 %
21.19 %
21.19 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.03 %
0.03 %
0.03 %
0.03 %
0.02 %
0.02 %
0.02 %
0.02 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
53.12 %
53.12 %
53.21 %
53.21 %
55.04 %
55.01 %
41.66 %
41.34 %
41.67 %
37.50 %
37.28 %
35.43 %
35.43 %
33.44 %
33.86 %
34.00 %
33.62 %
Others
11.56 %
11.56 %
9.81 %
9.81 %
9.48 %
9.51 %
22.86 %
23.18 %
22.85 %
31.98 %
33.18 %
36.74 %
36.74 %
45.36 %
44.93 %
44.79 %
45.17 %
No of Share Holders
11,643
12,824
13,004
13,004
14,380
14,700
14,689
14,912
14,796
14,648
14,250
13,908
14,015
13,882
13,913
14,086
14,158

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
30 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 May 2025 11.13 11.10
20 Mar 2025 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
20 Mar 2025 10.70 10.63
12 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Feb 2025 9.71 10.78
13 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Nov 2024 12.79 12.60
30 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2024 13.15 13.70
06 Mar 2024 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
06 Mar 2024 15.56 14.09

Announcements

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements Requirements) Regulations 2015.4 days ago
Closure of Trading Window5 days ago
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
Outcome Of Board Meeting Under Regulations 30 Read With 33 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 30, 2025
Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ended 31.03.2025May 20, 2025
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2Apr 30, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 30, 2025
General Announcement - Financials ResultsApr 28, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceApr 23, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 21, 2025
Closure of Trading WindowMar 25, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 20, 2025
Shareholder Meeting / Postal Ballot-Outcome of EGMMar 20, 2025
Intimation - Newspaper Publication Of Notice Of EGM Of The CompanyMar 01, 2025
Clarification Regarding Date Mentioned In The Covering Letter For Notice Of Extraordinary General Meeting (EGM)Mar 01, 2025
Notice Of Extra- Ordinary General Meeting Of The Company To Be Held On 20.03.2025Feb 25, 2025
Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Feb 19, 2025
Closure of Trading WindowFeb 14, 2025
Board Meeting Intimation for Raising Of Funds By Way Of Issue Of Equity Or Convertible Warrants On Preferential BasisFeb 14, 2025
Integrated Filing (Financial)Feb 12, 2025
Results For The Quarter And Nine Months Ended 31.12.2024Feb 12, 2025
Board Meeting Intimation for Un Audited Financials Results For The Quarter Ended 31.12.2024Feb 03, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 20, 2025
Closure of Trading WindowDec 29, 2024
Intimation Under Regulation 30 Of SEBI (Listing Obligations AndDisclosure Requirements) Regulations, 2015 - ''Issue Of World Health Organisation (WHO) G.M.P. Certificate.Nov 14, 2024
Outcome Of Board Meeting Under Regulations 30 Read With 33 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Nov 13, 2024
Board Meeting Intimation for For Approval Of Unaudited Financial Results For The Quarter Ended 30.09.2024Nov 07, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 18, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 30, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2024
Closure of Trading WindowSep 30, 2024
Intimation-Newspaper Publication Of Notice Of 33 Annual General Meeting Of The Company For The Financial Year 2023-24.Sep 10, 2024
Intimation Of Book Closure Regarding 33 Annual General Meeting:Sep 08, 2024
Submission Of 33Rd AGM Notice Which Is Dispatched To Shareholders Of The CompanySep 08, 2024
Reg. 34 (1) Annual Report.Sep 08, 2024
Nil Statement On Deviation Or Variation In Utilization Of Funds Raised Through Preferential Allotment:Aug 14, 2024
Outcome Of Board Meeting Under Regulations 30 Read With 33 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Aug 13, 2024
Board Meeting Intimation for Approval Of Un Audited Financial Results For The Quarter Ended 30.06.2024Aug 03, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Jul 19, 2024
Closure of Trading WindowJun 28, 2024
Announcement under Regulation 30 (LODR)-AllotmentJun 14, 2024
Outcome Of Board Meeting Under Regulations 30 Read With 33 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015May 28, 2024
Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ended 31.03.2024.May 21, 2024
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2Apr 30, 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 30, 2024
Compliance Under Regulation 7(3) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015Apr 30, 2024
Compliance As Per Regulation 40 (10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended 31.03.2024Apr 30, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Apr 21, 2024
Closure of Trading WindowMar 29, 2024
Outcome Of Circular Resolutions Passed By Board Of Directors Of The Company By Circulation On 13.02.2024 Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.Feb 13, 2024

Technical Indicators

RSI(14)
Neutral
54.92
ATR(14)
Volatile
0.65
STOCH(9,6)
Neutral
46.68
STOCH RSI(14)
Neutral
57.13
MACD(12,26)
Bullish
0.01
ADX(14)
Weak Trend
14.43
UO(9)
Bearish
65.64
ROC(12)
Downtrend But Slowing Down
-1.92
WillR(14)
Neutral
-34.76